KLK6 and bladder transitional cell carcinoma: TCGA revealed that KLK6 high expression in BLCA patients showed a shorter overall survival [HR = 1.74 (1.29-2.34), p < 0.001; Figure 3(a)], disease-specific survival [HR = 1.82 (1.27-2.60), p = 0.001; Figure 3(b)], and progress-free interval [HR = 1.61 (1.19-2.16), p = 0.002; Figure 3(c)] than those patients with KLK6 low expression.